How Can Constipation Be Improved? An Evidence-Based Review of Fiber, Probiotics, Senna, and Prescription Drugs

Reading the Evidence on Constipation: No Single Approach Works for Everyone

The conclusion in one sentence

Constipation should be managed by separately evaluating fiber properties, individual circumstances, specific microbial strains, and the evidence for medications. A single product or study should not be marketed as a solution that works for everyone. (PMID: 42198920；PMID: 42079003；PMID: 41769687)

Fiber cannot be divided simply into “effective” and “ineffective”

Soluble fiber is not the only kind that may help relieve constipation. The evidence instead favors making decisions according to a fiber’s physicochemical properties, the context in which it is used, and the individual’s response, rather than treating “it must be soluble” as a universal rule. (PMID: 42198920；PMID: 42079003)

Fiber supplements may offer some benefit overall, but the studies are heterogeneous and may also be affected by publication bias. Thus, “may help” does not mean that every fiber, at every dose, will produce the same result in every person with constipation. Bowel movements, bloating, and tolerability still need to be monitored in actual use. (PMID: 33192192)

The evidence for PHGG must likewise be understood within its proper limits. A study in a special postoperative population that combined PHGG with other interventions cannot establish that PHGG broadly improves constipation, gastrointestinal problems, diarrhea, glycemic control, and fat loss. Still less can it show that other soluble fibers cannot provide those benefits. Professor Lin’s qualified position—that the evidence is somewhat unclear, so trying it may be reasonable but overpromotion is not—is consistent with the current boundaries of the evidence. (PMID: 42400993)

Juice cannot replace an assessment of whole foods and chewing

Once fruits and vegetables have been juiced, “enzyme therapy” should not be promoted as if its clinical efficacy were established. Current data do not directly demonstrate that all enzymes in ordinary fruit and vegetable juices remain clinically effective after human digestion. Similarly, chewing ability is associated with cognitive outcomes, but no direct trial has shown that drinking fruit and vegetable juice causes cognitive decline. The more precise conclusion is that drinking juice is not equivalent to chewing whole fruits and vegetables—not that the difference between them has been proven to cause disease. (PMID: 41553031)

The relationship between frequent consumption of pure fruit juice and body weight also needs to be interpreted by population. A systematic review supports an association with body mass index in observational studies of children. In adults, the findings may be influenced by additional calories, while randomized trials have not shown a significant effect on weight. It is therefore too absolute to say that juice “inevitably makes everyone obese,” but treating it as a health drink that can be consumed without limit is equally inconsistent with the evidence. (PMID: 38227336)

Probiotics must be judged by strain and trial endpoint

“Probiotics may be beneficial” cannot be translated into “all probiotics treat constipation.” The literature as a whole suggests possible benefit, but the evidence remains limited and heterogeneous. Interpretation must return to the particular strain, product combination, population, and primary endpoint studied. (PMID: 41769687；PMID: 41807013)

Consider Bifidobacterium lactis HN019. The primary analysis of a human trial did not show superiority over placebo, and a newer, large triple-blind trial likewise found no advantage. Claiming that human trials have “proven” HN019 improves functional constipation therefore goes beyond the study findings. (PMID: 29227175；PMID: 39356506)

In children with chronic functional constipation, adding a probiotic mixture containing BB536 to PEG did not produce a significant additional benefit; PEG remained the principal treatment supported by the study. (PMID: 28270173) As for BB12, the current search results are not sufficient to support the strict universal claim that “no human trial of any kind exists.” They also do not permit findings from other strains to be transferred directly to BB12. (PMID: 41807013)

The favorable signal for kefir comes from a pilot study whose authors themselves called for confirmation in subsequent controlled trials; the overall evidence remains limited. Kefir may therefore be a worthwhile subject for further research, but it is not yet a constipation therapy established by adequate controlled trials. (PMID: 25599776；PMID: 41827605)

Senna, melanosis coli, and stimulant laxatives

Long-term senna use has a clinical association with melanosis coli, and a case report has shown that the pigmentation can regress after senna is stopped. A case report, however, cannot estimate the incidence among all users or guarantee complete reversibility in every situation. (PMID: 39282237)

There is no need to create alarm about cancer risk. A systematic review has not established a definite association between anthraquinone laxative use and colorectal cancer, supporting Professor Lin’s objection to equating melanosis coli directly with cancer. Nevertheless, existing confidence intervals still allow for a difference in risk, and the literature calls for higher-quality studies. Saying the two are “certainly completely unrelated” would therefore remain too categorical. (PMID: 35040201)

Scientific understanding of long-term stimulant laxative use has evolved. A newer critical review does not support absolute claims that long-term use inevitably damages the bowel, inevitably causes dependence, or inevitably worsens chronic constipation; it also argues that the benefits of long-term use should be reassessed. This represents an update in the literature that revises earlier safety concerns. It should not be portrayed as though Professor Lin himself had rewritten his original historical position. (PMID: 38887508)

Prescription treatments with direct evidence also have costs

Plecanatide, marketed as Trulance, is a uroguanylin analog and GC-C agonist that promotes intestinal fluid secretion through the relevant signaling pathway. Integrated evidence for chronic idiopathic constipation shows that it improves bowel-movement frequency and stool consistency more than placebo, in line with Professor Lin’s reading of the clinical trials. (PMID: 41604554；PMID: 42038325)

Adverse effects must be considered alongside efficacy. The most common important adverse-event signal for Plecanatide is diarrhea, and meta-analytic findings point in the same direction as real-world pharmacovigilance data. This is a reminder that even an evidence-based prescription drug does not offer “benefits only.” A healthcare professional should assess its use according to symptoms, contraindications, and tolerability. (PMID: 41604554；PMID: 39654622)

The bottom line for practical decisions

When evaluating a constipation product, first ask which type of fiber, which strain, and which population were studied, and whether the primary endpoint truly outperformed placebo. Then distinguish pilot research and studies in special populations from broader evidence that can reasonably be generalized. If constipation persists, symptoms change, or long-term medication becomes necessary, do not rely on advertising or infer efficacy from a single ingredient alone; seek professional evaluation. The value of an evidence-based conclusion is not that it prescribes the same answer for everyone, but that it clearly separates “possibly effective,” “not yet established,” and “directly supported.”